Ocular Therapeutix Inc
(NASDAQ : OCUL)

( )
OCUL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
0.49%14.4214.2%$227.85m
SHPGShire PLC Sponsored ADR
-0.22%142.840.4%$213.78m
PRGOPerrigo Co. Plc
-1.49%77.436.4%$150.76m
MNKMallinckrodt Plc
0.22%37.2017.7%$117.37m
UTHRUnited Therapeutics Corporation
-0.43%130.7213.9%$87.52m
JAZZJazz Pharmaceuticals Plc
-0.16%146.502.2%$80.04m
ENDPEndo International Plc
-0.48%8.348.9%$70.27m
HZNPHorizon Pharma plc
-1.45%12.937.6%$64.54m
ALRAlere Inc.
-0.35%49.392.7%$63.82m
PRXLPAREXEL International Corporation
-0.08%87.667.9%$62.65m
ICPTIntercept Pharmaceuticals, Inc.
-0.14%106.9422.1%$62.05m
MYOKMyoKardia, Inc.
0.80%44.153.0%$54.03m
MDCOMedicines Company
1.92%36.0922.3%$43.38m
PTLAPortola Pharmaceuticals, Inc.
0.59%56.288.9%$42.36m
ICLRICON Plc
-1.03%106.784.2%$41.60m

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its products include dextenza, sustained release travopost, and posterior segment injections. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.